Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H26N2O2 |
Molecular Weight | 362.4647 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(O[C@H]1CN2CCC1CC2)N3CCC4=C(C=CC=C4)[C@@H]3C5=CC=CC=C5
InChI
InChIKey=FBOUYBDGKBSUES-VXKWHMMOSA-N
InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
Molecular Formula | C23H26N2O2 |
Molecular Weight | 362.4647 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.rxlist.com/vesicare-drug.htm
https://www.drugs.com/mtm/solifenacin.html
http://www.wikidoc.org/index.php/Solifenacin
Curator's Comment: description was created based on several sources, including:
http://www.rxlist.com/vesicare-drug.htm
https://www.drugs.com/mtm/solifenacin.html
http://www.wikidoc.org/index.php/Solifenacin
Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23094215 http://www.ics.org/Abstracts/Publish/46/000185.pdf
Curator's Comment: Known to be CNS penetrant in rat. Human data not available
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL245 |
10.0 nM [Ki] | ||
125.0 nM [Ki] | |||
25.0 nM [Ki] | |||
7.73 null [pKi] | |||
7.46 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VESICARE Approved UseVESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency (1) Launch Date2004 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15206986 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
SOLIFENACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
820 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15206986 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
SOLIFENACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
50.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15206986 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
SOLIFENACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
SOLIFENACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg single, oral Highest studied dose |
healthy, 19-40 |
|
30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
healthy, 20-35 |
|
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Angioedema, Anaphylactic reaction... AEs leading to discontinuation/dose reduction: Angioedema Sources: Anaphylactic reaction (rare) |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Dry mouth... AEs leading to discontinuation/dose reduction: Dry mouth (1.5%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Angioedema | Disc. AE | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Anaphylactic reaction | rare Disc. AE |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Dry mouth | 1.5% Disc. AE |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0 |
not significant | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0 |
not significant | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0 |
not significant | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0 |
not significant | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0 |
yes [Inhibition 1.04 uM] |
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_pharmr.pdf#page=35 Page: 35.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Drug forecast--solifenacin: an investigational anticholinergic for overactive bladder. | 2004 May |
|
Solifenacin in overactive bladder: a viewpoint by Hashim Hashim. | 2005 |
|
Solifenacin in overactive bladder syndrome: a viewpoint by Scott Serels. | 2005 |
|
Solifenacin in overactive bladder syndrome. | 2005 |
|
Overactive bladder in the elderly: a guide to pharmacological management. | 2005 |
|
[Neurological aspect of the hyperactive urinary bladder syndrome]. | 2005 |
|
Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. | 2005 |
|
Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. | 2005 Apr 4 |
|
Solifenacin and darifenacin for overactive bladder. | 2005 Aug |
|
Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. | 2005 Jan |
|
New drugs: acamprosate calcium and solifenacin succinate. | 2005 Jan-Feb |
|
Darifenacin in the treatment of overactive bladder. | 2005 Jul |
|
Effect of age on the pharmacokinetics of solifenacin in men and women. | 2005 May |
|
Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. | 2005 May |
|
[Drug discovery in the fields of urology: tamsulosin and solifenacin]. | 2005 Nov |
|
The Q-T interval and antimuscarinic drugs. | 2005 Nov |
|
Solifenacin versus tolterodine--a head-to-head study: finally! But not final? | 2005 Nov |
|
Solifenacin in the management of the overactive bladder syndrome. | 2005 Oct |
|
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists. | 2005 Oct 20 |
|
Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. | 2005 Sep |
|
Role of muscarinic receptor antagonists in urgency and nocturia. | 2005 Sep |
|
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. | 2005 Sep |
|
Gateways to clinical trials. | 2006 Apr |
|
The causes and consequences of overactive bladder. | 2006 Apr |
|
New developments in the treatment of urinary incontinence. | 2006 Dec |
|
Solifenacin succinate (VESIcare): overactive bladder therapy. | 2006 Dec |
|
New drugs 06, part I. | 2006 Feb |
|
Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. | 2006 Jan |
|
Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70. | 2006 Jan |
|
Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice. | 2006 Jul |
|
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder]. | 2006 Jul |
|
[Oral anticholinergics in overactive bladder]. | 2006 Jul |
|
Gateways to clinical trials. | 2006 Jul-Aug |
|
Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. | 2006 Jun |
|
Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. | 2006 Jun |
|
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. | 2006 Mar |
|
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. | 2006 Mar |
|
Gateways to clinical trials. | 2006 May |
|
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). | 2006 Nov |
|
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? | 2006 Nov |
|
Solifenacin. | 2006 Nov |
|
Solifenacin succinate for the treatment of symptoms of overactive bladder. | 2006 Sep |
|
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. | 2006 Sep |
|
Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. | 2007 Feb 28 |
|
Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. | 2007 Jan |
|
Redefining response in overactive bladder syndrome. | 2007 Jan |
|
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. | 2007 Jan |
|
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. | 2007 Mar |
|
An unusual cause of postoperative detrusor overactivity. | 2007 Oct |
|
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. | 2007 Sep |
Patents
Sample Use Guides
5 mg tablet taken once daily, and if well tolerated may be increased to 10 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15178371
The inhibitory effect of solifenacin (dose range: 10^-10 - 10^-6 M) for bladder smooth muscle cells (pK(i)=8.12) was 3.6-fold more potent than that for salivary gland cells (pK(i)=7.57).
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:28:05 GMT 2025
by
admin
on
Mon Mar 31 18:28:05 GMT 2025
|
Record UNII |
A8910SQJ1U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G04CA53
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
||
|
NDF-RT |
N0000000125
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
||
|
WHO-ATC |
G04BD08
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
||
|
NDF-RT |
N0000000125
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
||
|
WHO-VATC |
QG04CA53
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
||
|
LIVERTOX |
NBK548716
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
||
|
NDF-RT |
N0000000125
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
||
|
WHO-VATC |
QG04BD08
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
||
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
||
|
NDF-RT |
N0000175700
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
322167
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
C441209
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
Solifenacin
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
m10108
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | Merck Index | ||
|
8155
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
2457
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
DB01591
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
100000084906
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
SUB21589
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
DTXSID3048289
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
242478-37-1
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
7483
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL1734
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
759144
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
A8910SQJ1U
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
C75284
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
A8910SQJ1U
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
154059
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
SOLIFENACIN
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
PRIMARY | |||
|
477364
Created by
admin on Mon Mar 31 18:28:05 GMT 2025 , Edited by admin on Mon Mar 31 18:28:05 GMT 2025
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Appears to be more bladder-selective for the M3 receptor relative to salivary glands.eptor
Ki
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
TARGET->WEAK INHIBITOR |
Ki
|
||
|
BINDER->LIGAND |
in vivo
BINDING
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
major in urine
MAJOR
PLASMA; URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
major in urine
MAJOR
PLASMA; URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE ACTIVE -> PARENT |
occurs at low concentrations and unlikely to contribute significantly to clinical activity
MINOR
PLASMA
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||